Skip to Main Content

Ocular Therapeutix failed for a second time to secure approval of its eye drug Dextenza. On Tuesday, the FDA rejected the drug, citing unresolved problems with manufacturing and quality control testing.

Shares of Ocular were halted at $7.60 in Tuesday’s after-market session. The company has approximately $2 per share in cash on hand.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!